This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Ursodeoxycholic Acid (Liquid Formulation)
The original formulation from Retrophin is under the Cholbam profile.
Ursodeoxycholic acid is a naturally occurring hydrophilic bile acid derived from cholesterol.
Retrophin and Asklepion
In June 2016, Retrophin announced the signing of a definitive agreement to purchase the rights, titles, and ownership of a liquid formulation of ursodeoxycholic acid from Asklepion Pharmaceuticals.
Under the terms of the agreement, Retrophin made an upfront payment of $0.5 million and will make future payments of up to $23.5 million based on cumulative sales milestones of liquid ursodeoxycholic acid in PBC. Asklepion will be eligible to receive incremental milestone payments of up to $35.0 million in aggregate upon successful development and commercialization, including cumulative sales milestones, of liquid ursodeoxycholic acid in additional indications. Retrophin will assume all future program costs and pay Asklepion tiered royalties on future product sales.
Partners: Asklepion Pharmaceuticals, LLC
Ursodeoxycholic Acid News
Pink Sheet In Brief: Axcan's Urso
Pink Sheet US FDA, Advisory Committees Rarely Disagree
Additional information available to subscribers only: